DESCRIPTION AMINOALCOHOL DERIVATIVES FIELD OF THE INVENTION This invention relates to new aminoalcohol derivatives and salts thereof which are beta-3 (P3) adrenergic receptor agonists and useful as a medicament. BACKGROUND OF THE INVENTION International Publication No. WO 90/06299, published June 14, 1990, describes derivatives of phenylethanolamines as having an effect on the metabolism, preferably reduction of the blood sugar level and body fat, International Publication No. WO 02/32897, published April 25, 2002, describes derivatives of alpha-aryl ethanolamines useful as P3 adrenergic receptor agonists, and International Publication No. WO 2004/002939, published January 8, 2004, describes aminoalcohol derivatives useful as P3 adrenergic receptor agonists. DISCLOSURE OF THE INVENTION This invention relates to new aminoalcohol derivatives which are P3 adrenergic receptor agonists and salts thereof. More particularly, it relates to new aminoalcohol derivatives and salts thereof which are useful for the treatment and/or prevention of gastro-intestinal disorders, ulcer, overactive bladder, micturiation disorders, pancreatitis, obesity, diabetes, etc., to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of the aforesaid disorders in a human being or an animal. One object of this invention is to provide new and useful aminoalcohol derivatives and salts thereof which are useful for the treatment and/or prevention of the aforesaid disorders. Another object of this invention is to provide processes for the preparation of said aminoalcohol derivatives and salts thereof. A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said aminoacohol derivatives and salts thereof. Still further object of this invention is to provide a therapeutical method for the treatment and/or prevention of the aforesaid diseases in a human being or an animal, using said aminoalcohol derivatives and salts thereof. The object aminoalcohol derivatives of this invention are new and can be represented by compound of the following formula [I]: X is bond, -CH2-, -0- or -NH-, R11 and R12 are each independently hydrogen, halogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, nitro, amino or (lower alkylsulfonyl)amino, R^ is hydrogen or optionally substituted lower alkyl, RJ is hydrogen or an amino protective group, R*, RJ and R° are each independently hydrogen or optionally substituted lower alkyl, R7 is -Z-R13, in which Z is bond, -(CH2)n- (in which n is 1, 2, 3 or 4) or -OCH2-, and R.13 is carboxy, lower alkoxycarbonyl, (lower alkylsulfonyl)carbamoyl or lower alkanoylsulfamoyl, R8 is -Y-R9, in which Y is bond, -CH2-, -0-, -S-, -SO-, -S02-, -NH- or -N- (in which R^ is lower alkyl, cyclo(lower)alkyl or aryl), and R9 is hydrogen, lower alkyl, cyclo(lower)alkyl, mono(or di or tri)halo(lower)alkyl, lower alkanoyl, lower alkenyl, lower alkoxy(lower)alkyl, nitro, aryl or a heterocyclic group, and RH is hydrogen, lower alkyl, lower alkoxy, amino or mono(or di)lower(alkyl)amino, provided that when R' is carboxy or lower alkoxycarbonyl, then (i) R^ is lower alkyl, (ii) R4 is substituted lower alkyl, (iii) R° is optionally substituted lower alkyl, or (iv) R1 and R1^ are each hydrogen, R^ is hydrogen, R , R5 and R° are each hydrogen, and p R° is cyclo(lower)alkyl, methylthio, ethylthio, methylsulfonyl, ethylsulfonyl, lower alkoxy(lower)alkylthio, amino, mono(or di)(lower)alkylamino, lower alkanoylamino, cyclo(lower)alkylamino, mono(or di or tri)halo (lower)alkyl, lower alkenyl, lower alkoxy(lower)alkyl, tetrahydropyranyloxy, thienyl, pyridyl or pyridyloxy, or a salt thereof. According to this invention, the object compounds can be prepared by processes which are illustrated in the following schemes. [Ie] or a salt thereof wherein , X, R1, R2, R3, R4, R5, R6, R7, R8, R11 and R12 are each as defined above, R3 is an amino protective group, R^ is lower alkyl, and X-j_ is a leaving group. As to the starting compounds [II], [III], [la], [IV], [V], [VI] and [Ic], some of them are novel and can be prepared by the procedures described in the Preparations and Examples mentioned below or a conventional manner. In the above and subsequent description of the present specification, suitable examples of the various definition to be included' within the scope of the invention are explained in detail in the following. The term "lower" is intended to mean a group having 1 to 8, preferably 1 to 7, more preferably 1 to 6, most preferably 1 to 4, carbon atom(s), unless otherwise indicated. Suitable "lower alkyl" and "lower alkyl" moiety in the terms of "(lower alkylsulfonyl)carbamoyl", "mono(or di)lower(alkyl)amino", "(lower alkylsulfonyl)amino", etc. may include straight or branched one having 1 to 8, preferably 1 to 7, more preferably 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pehtyl, 1-methylpentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl, heptyl, isoheptyl, octyl, isooctyl and the like. Suitable "lower alkoxy" moiety in the terms of "lower alkoxycarbonyl", "lower alkoxy(lower)alkyl", etc. may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy, hexyloxy and the like, in which preferable one is methoxy or ethoxy. Suitable "lower alkanoyl" moiety in the term of "lower alkanoylsulfamoyl" may include formyl, acetyl,. propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl and the like. Suitable "cyclo (lower)alkyl" may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, in which preferable one is cyclo(C3-C7)alkyl, and most preferable one is cyclopentyl or cyclohexyl. Suitable "mono(or di or tri)halo(lower)alkyl" may include chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1 or 2-chloroethyl, 1 or 2-bromoethyl, 1 or 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3-fluoropropyl and the like. Suitable "lower alkenyl" may include vinyl, l-(or 2-)propenyl, 1- (or 2- or 3-)butenyl, 1-(or 2- or 3- or 4-)pentenyl, 1-(or 2- or 3- or 4- or 5-)hexenyl, l-(or 2-)methylvinyl, ethylvinyl, 1-(or 2- or 3-)methyl-l-(or 2-)propenyl, 1-(or 2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)methyl-l-(or 2- or 3-)butenyl and the like, in which more preferable example may be C2-C4 alkenyl. Suitable "halogen" may be fluoro, chloro, bromo and iodo, in which preferable one is chloro. Suitable "aryl" may include phenyl, naphthyl, indenyl, anthryl and the like, in which preferable one is Cg-C]_o aryl, and more preferable one is phenyl. Suitable "heterocyclic group" may be one containing at least one hetero atom selected from nitrogen, sulfur and oxygen atom, and may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group, and preferable heterocyclic group may be N-containing heterocyclic group such as unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl [e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.], tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.; saturated 3 to 7-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, homopiperazinyl, etc.]; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, imidazopyridyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g. tetrazolo[1,5-b]pyridazinyl, etc.], quioxalinyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc. ; saturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, lH-tetrahydropyranyl, tetrahydrofuranyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms, for example, thienyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g. 1,2,4- oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.], oxazolinyl [e.g. 2-oxazolinyl, etc.], etc. ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc. ] ; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzofurazanyl, benzoxazolyl, benzoxadiazolyl, etc.]; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g. 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.], etc. ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g. thiazolidinyl, etc.]; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g. benzothiazolyl, benzothiadiazolyl, etc.]; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms [e.g. benzofuranyl, benzodioxolyl, chromanyl, etc.] and the like, in which preferable one is thienyl. The term "optionally substituted" refers to "unsubstituted or substituted by one or more suitable substituent(s)". Suitable "optionally substituted lower alkyl" may include lower alkyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl and the like, in which preferable one is hydroxymethyl. Suitable "leaving group" may include hydroxy, reactive group derived from hydroxy and the like. -Suitable "reactive group derived from hydroxy" may include acid residue and the like. Suitable "acid residue" may include halogen (e.g. fluoro, chloro, bromo, iodo), acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, trifluoromethanesulfonyloxy, etc.) and the like. Suitable example of "amino protective group" moiety may be common amino protective group such as substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxycarbonyl [e.g. tert-butoxycarbonyl, tert-amyloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl. [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.], and the like, in which preferable one is tert-butoxycarbonyl. Suitable salts of the object aminoalcohol derivative [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, citrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc., an alkali metal salt [e.g. sodium salt, potassium salt, etc.] or the like. The Processes 1 to 5 for preparing the object compounds of the present invention are explained in detail in the following. Process 1 The object compound [I] or a salt thereof can be prepared by reacting a compound [II] with a compound [III] or a salt thereof. Suitable salt of the compound [III] may be the same as those exemplified for the compound [I]. The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like. The reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isoprppanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating. Process 2 The object compound [lb] or a salt thereof can be prepared by subjecting a compound [la] or a salt thereof to elimination reaction of the amino protective group. Suitable salts of the compounds [la] and [lb] may be the same as those exemplified for the compound [I]. This reaction can be carried out in a similar manner to that of Example 6 mentioned below. Process 3 The object compound [I] or a salt thereof can be prepared by reacting a compound [IV] or a salt thereof with a compound [V] or a salt thereof. Suitable salts of the compounds [I], [IV] and [V] may be the same as those exemplified for the compound [I]- This reaction can be carried out in a similar manner to that of Preparation 14 mentioned below. Process 4 The object compound [I] or a salt thereof can be prepared by reacting a compound [IV] or a salt thereof with a compound [VI] or a salt thereof. Suitable salts of the compounds [I] , [IV] and [VI] may be the same as those exemplified for the compound [I]. This reaction can be carried out in a similar manner to that of Example 1 mentioned below. Process 5 The object compound [Ie] or a salt thereof can be prepared by subjecting a compound [Ic] or a salt thereof to deesterification reaction followed by subjecting a compound [Id] or a salt thereof to elimination reaction of the amino protective group. Suitable salts of the compound [Ie], [Ic] and [Id] may be the same as those exemplified for the compound [I]. These reactions can be carried out in a similar manner to that of Example 4 mentioned below. The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary. It is to be noted that the compound [I] and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention. It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to the effect of the light, acid base or the like, and the compound obtained as the result of said isomerization or rearrangement if also included within the scope of the present invention. It is also to be noted that the solvating form of the compound [I] (e.g. hydrate, etc.) and any form of the crystal of the compound [I] are included within the scope of the present invention. The object compound [I] or a salt thereof are useful for the treatment and/or prevention of gastro-intestinal disorders in human beings or animals, and more particularly for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholantitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, or the like; for the treatment and/or prevention of overactive bladder such as nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prostatitis, prostatic hypertrophy or the like; for the treatment and/or prevention of micturiation disorder such as stress incontinence, urge incontinence, mixed incontinence, functional incontinence, overflow incontinence; for the treatment and/or prevention of pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, melancholia, depression or the like; for the treatment and/or prevention of diseases as the result of insulin resistance (e.g. hypertension, hyperinsulinemia, etc.); for the treatment and/or prevention of neurogenetic inflammation; and for reducing a wasting condition, and the like. Additionally, P3 adrenergic receptor agonists are known to lower triglyceride and cholesterol levels and to raise high density lipoprotein levels in mammals (US Patent No. 5,451,677). Accordingly, the object compound [I] is useful in the treatment and/or prevention of conditions such as hyper-triglyceridaemia, hypercholesterolaemia and in lowering high density lipoprotein levels as well as in the treatment of atherosclerotic and cardiovascular diseases and relates conditions. Moreover, the object compound [I] is useful for inhibiting uterine contractions, preventing premature labor, and treating and preventing dysmenorrhea. For therapeutic purpose, the compound (I) and a pharmaceutically acceptable salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, internal, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration. The pharmaceutical preparations may be solid, semi-solid or solutions such as capsules, tablets, pellets, dragees, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives. While the dosage of the compound (I) will vary depending upon the age and condition of a patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating diseases such as pollakiurea, urinary incontinence and the like. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day. In order to show the usefulness of the compound [I] for the prophylactic and therapeutic treatment of above-mentioned disease in human being or animals, a representative compound of the compound [I] was tested on the following pharmaceutical test. Test Effect on the increase in intravesical pressure induced by carbachol in anesthetized dog Test compound (1) 4'-[2-[[(IS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]-amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylic acid hydrochloride (2) 4'-[2- [ [ (lS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]-amino]ethyl]-3-isobutyl-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride (3) 3-(Cyclohexyloxy)-4'-[2-[[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-N-(methylsulfonyl)-4-biphenylcarboxamide dihydrochloride Test Method Female Beagle dogs weighing 8.0-15.0 kg were fasted for 24 hours and maintained under halothane anesthesia. A 12F Foley catheter was lubricated with water soluble jelly, inserted into the urethral orifice and advanced approximately 10 cm until the balloon tip was placed well inside the bladder. The balloon was then inflated with 5 ml of room air and catheter slowly withdrawn just part the first resistance that was felt at the bladder neck. Urine was completely drained out through the catheter, and 30 ml of biological saline was infused. The catheter was connected to pressure transducer, and intravesical pressure (IVP) was continuously recorded. The test compound was administered intravenously at 30 minutes before the administration of carbachol (1.8 (ig/kg) . Percent inhibition of IVP increase by test compound was calculated by dividing IVPa (IVP increase induced by carbachol after test compound administration) by IVPb (IVP increase induced by carbachol just before test compound administration). Test Results Preferred embodiments of the object compound [I] are as follows: R7 is -Z-R13, in which Z is bond or ~(CH2)n- (in which n is 1), and R1^ is carboxy or lower alkoxycarbonyl (more preferably C^_-C^ alkoxycarbonyl, most preferably methoxycarbonyl or ethoxycarbonyl). More preferred embodiments of the object compound [I] are as follows: X is bond, R^ and R12 are each independently hydrogen or halogen, R3 is hydrogen, R4 is hydrogen, R5 is optionally substituted lower alkyl (more preferably cl"c4 alkyl/ most preferably methyl), R8 is -Y-R9, in which Y is bond, -Ct^-, -0- or -S-, and R9 is lower alkyl (more preferably C1~C6 alkyl, most preferably propyl or isopropyl), cyclo(lower)alkyl (more preferably cyclo(C3~Cg)alkyl, most preferably preferably C1-C6 alkoxy (C1-C6) alkyl, most preferably 2-ethoxyethyl), and R11 is hydrogen. Other preferred embodiments of the object compound [I] are as follows: R7 is -Z-R13, in which Z is bond or _(CH2)n~ (in which n is 1), and R13 is (lower alkylsulfonyl)carbamoyl (more preferably (C^-C^ alkylsulfonyl)carbamoyl, most preferably (methylsulfonyl)carbamoyl or (ethylsulfonyl)-carbamoyl) or lower alkanoylsulfamoyl (more preferably C-^-C^ alkanoylsulfamoyl, most preferably acetylsulfamoyl). More preferred embodiments of the compound [I] are as follows: X is bond, R1 and R1^ are each independently hydrogen or halogen, R3 is hydrogen, R4 is hydrogen, R8 is -Y-R9, in which Y is bond, -CH2-, -0-, -S- or -NH-, and R9 is lower alkyl (more preferably C1-C6 alkyl, most preferably isopropyl, isobutyl or isopentyl) or cyclo(lower)alkyl (more preferably cyclo(C3-C5)alkyl, most preferably cyclopentyl or cyclohexyl), and R11 is hydrogen. The following Preparations and Examples are given for the purpose of illustrating this invention. The group of "carbamoyl" aforementioned may be hereinafter referred as a group of "aminocarbonyl". Preparation 1 To a mixture of (4-bromophenyl)acetic acid (10 g), and (1R,2S)-norephedrine (5.8 g) and 1-hydroxybenzotriazole (6.2 g) in N,N-dimethylformamide (100 ml) was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (8.8 g), and the mixture was stirred at room temperature for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed successively with sodium bicarbonate solution and brine, dried over magnesium sulfate and evaporated under reduced pressure to give an amide product. To a tetrahydrofuran (100 ml) solution of the product, 2M-boran-dimethylsulfide complex in tetrahydrofuran (100 ml) was added at room temperature, and the mixture was refluxed for 30 minutes. To the mixture, 12N-hydrochloride acid (50 ml) was added dropwise below 10°C, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture, 3N aqueous sodium hydroxide solution below 10°C was added and di-tert-butyl dicarbonate (10 g) was added portionally at room temperature. The pH value was kept between 7 to 8 by using IN aqueous sodium hydroxide solution. The mixture was stirred at room temperature for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give 4-[2-[[(IS,2R)-2-hydroxy-2-phenyl-l-methylethyl](tert-butyloxycarbonyl)amino]ethyl]phenyl bromide (16 g). MS (m/z): 434 (M+H) Preparation 2 A solution of (IS)-l-hydroxymethyl-2-(4-iodophenyl)-ethylamine (5 g), and (R)-styrene oxide (2 g) in ethanol (50 ml) was refluxed for 18 hours. The mixture was evaporated in vacuo. The residual oil was diluted in tetrahydrofuran (50 ml). To the solution was added di-tert-butyl dicarbonate (5 g) at room temperature, and the mixture was stirred at the same temperature for 12 hours. The resulting mixture was evaporated under pressure and the residue was purified by column chromatography on silica gel to give 4-[(2R)-2-[[(2S)-2-hydroxy-2-phenylethyl](tert-Uutyloxycarbonyl)amino]-2-(hydroxymethyl)ethyl]phenyl iodide (5.5 g). MS (m/z): 498 (M+H) Preparation 3 To a mixture of magnesium (1.61 g) in tetrahydrofuran (10 ml) was added a solution of isoamyl bromide (5.0 g) in tetrahydrofuran (23 ml) dropwise at room temperature under nitrogen, and the mixture was refluxed for 0.5 hour and cooled to room temperature. The mixture was transferred via a syringe to a solution of 4-bromo-2-fluorobenzoic acid (2.5 g) in tetrahydrofuran (15 ml) at 4-10°C. The resulting mixture was stirred at room temperature for 16 hours. To the reaction mixture was added water (200 ml) dropwise with ice-cooling. The aqueous solution was acidified with 6N aqueous hydrochloride solution and extracted with ethyl acetate (150 ml x 2). The combined organic layers were washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform/methanol = 10/1) to give 4-bromo-2-(3-methylbutyl)benzoic acid (1.35 g) MS (m/z): 269, 271 (M-H)~ Preparation 4 To a suspension of 4-bromo-2-(3-methylbutyl)benzoic acid (1.3 g) and methanesulfonamide (365 mg) in N,N-dimethylformamide (12 ml) was added 1-ethyl-3- (3-dimethylaminopropyl)carbodiimide hydrochloride (735 mg) and 4-dimethylaminopyridine (469 mg), and stirred at 30°C for 16 hours. The mixture was diluted with ethyl acetate, washed with IN aqueous hydrochloride solution, water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate =* 2/1) to give 4-bromo-2-(3-methylbutyl)-N-(methylsulfonyl)benzamide (1.25 g). MS (m/z): 346, 348 (M-H)~ Preparation 5 The following compound was obtained according to a similar manner to that of Preparation 4. 4-Bromo-2-isobutyl-N-(methylsulfonyl)benzamide MS (m/z): 332, 334 (M-H)~ Preparation 6 To a solution of 4-bromo-2-(3-methylbutyl)-N- (methylsulfonyl)benzamide (1. 22 g) in 1,4-dioxane (22 ml) was added bis(pinacolate)diboron (890 mg), dichlorobis- (triphenylphosphine)palladium(II) (172 mg) and potassium acetate (1.38 g), and the mixture was stirred at 90°C for 2 hours under nitrogen. The mixture was diluted with ethyl acetate, washed with IN aqueous hydrochloride solution, water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give 2-(3-methylbutyl)-N-(methylsulfonyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (1.75 g) which was used without any further purifications. MS (m/z): 394 (M-H)~ Preparation 7 The following compound was obtained according to a similar manner to that of Preparation 6. 2-Isobutyl-N-(methylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide MS (m/z): 380 (M-H)~ Preparation 8 To a solution of 4-bromo-2-fluorobenzoic acid (1 g) in pyridine (5 ml) was added isopropylamine (1.94 ml) at room temperature and the mixture was stirred at 100°C overnight. The mixture was poured into aqueous hydrochloric acid (IN) and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give 4-bromo-2- (isopropylamino) benzoic acid (218 mg). . (-)ESI-MS (m/z): 256 (M-H)~ Preparation 9 To a suspension of 4-bromo-2-(isopropylamino)benzoic acid (448 mg) and potassium carbonate (480 mg) in N,N-dimethylformamide (9 ml) was added methyl iodide (162 jal) at room temperature and the mixture was stirred at the same temperature for 1 hour. To the mixture was added water (20 ml) and extracted with mixed solvent (hexane/ethyl acetate = 1/1). The organic layer was washed with brine, dried over magnesium sulfate and evaporated to give methyl 4-bromo-2- (isopropylamino)benzoate (443 mg). NMR (CHCI3, 6): 1.27 (6H, d, J=6.2Hz), 3.62-3.71 (1H, m), 3.84 (3H, s), 6.64 (1H, dd, J=8.5, 1.9Hz), 6.83 (1H, d, J=1.8Hz), 7.70-7.75 (2H, m) Preparation 10 To a solution of methyl 4-bromo-2-(isopropylamino)-benzoate (433 mg) in 1,2-dimethoxyethane (6.5 ml) were added [4-[2-[benzyl(tert-butoxycarbonyl)amino]ethyl]phenyljboronic acid (848 mg), tetrakis(triphenylphosphine)palladium (184 mg) and aqueous solution of sodium carbonate (2M, 3.5 ml), and the mixture was stirred at 70°C for 2 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 17/3) to give methyl 4'-[2-[benzyl(tert-butoxycarbonyl)amino]ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (768 mg). (+)ESI-MS (m/z): 503 (M+H)+ Preparation 11 To a solution of methyl 4'-[2-[benzyl(tert-butoxycarbonyl) amino]ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (768 mg) in tetrahydrofuran (8 ml) was added 4N hydrogen chloride solution in 1,4-dioxane (8 ml) at 0°C, and the mixture was stirred at room temperature overnight. The mixture was evaporated under reduced pressure and the residue was diluted with chloroform and water. The mixture was basified with aqueous solution of sodium hydroxide (IN) and the organic layer was separated, dried over magnesium sulfate and evaporated under reduced pressure to give methyl 4'- [2-(benzylamino)ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (600 mg). (+)ESI-MS (m/z): 403 (M+H)+ Preparation 12 To a solution of tert-butyl [2-(4-bromophenyl)ethyl]-[(2R)-2-hydroxy-2-phenylethyl]carbamate (3.20 g) in dichloromethane (40 ml) were added 3,4-dihydro-2H-pyran (1.28 g) and pyridinium p-toluenesulfonate (191 mg) at room temperature and the mixture was stirred at the same temperature for 5 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated under reduced pressure to give tert-butyl [2-(4-bromophenyl)ethyl] [ (2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]carbamate (4.11 g). (+)ESI-MS (m/z): 526 (M+Na)+ Preparation 13 The following compound was obtained according to a similar manner to that of Example 3. tert-Butyl [2- [4- (2,2-dimethyl-4-oxo-4H-l,3-benzodioxin-7-yl)phenyl]ethyl][(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]carbamate (+)ESI-MS (m/z): 624 (M+Na)+ Preparation 14 To a solution of tert-butyl [2-(4-bromophenyl)ethyl]-[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-carbamate (620 mg) in 1,2-dimethoxyethane (7 ml) were.added [3-(cyclohexyloxy)-4- (methoxycarbonyl)phenyl]boronic acid (410 mg), tetrakis (triphenylphosphine)palladium (99 mg) and aqueous solution of sodium carbonate (2M, 1.35 ml), and the mixture was stirred at 75°C for 5 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 9/1) to give methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-(cyclohexyloxy)-4-biphenylcarboxylate (672 mg). (+)ESI-MS (m/z): 680 (M+Na)+ Preparation 15 The following compound was obtained according to a similar manner to that of Example 10. 4'-[2- [ (tert-Butoxycarbonyl) [(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-(cyclohexyloxy)-4-biphenylcarboxylic acid (-)ESI-MS (m/z): 642 (M-H)~ Preparation 16 To a solution of tert-butyl [2-[4-(2,2-dimethyl-4-oxo-4H-l,3-benzodioxin-7-yl)phenyl]ethyl][(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]carbamate (1.32 g) in methanol (15 ml) was added potassium carbonate (455 mg) at room temperature and the mixture was stirred at room temperature for 15 hours. The mixture was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, and washed with water, brine and aqueous hydrochloric acid solution (0.1N). The organic layer was dried over sodium sulfate and evaporated under reduced pressure to give methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-hydroxy-4-biphenylcarboxylate (1.11 g). <+)ESI-MS (m/z): 598 (M+Na)+ Preparation 17 To a solution of methyl 4'-[2-[ (tert-butoxycarbonyl) [(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2- yloxy)ethyl]amino]ethyl]-3-hydroxy~4-biphenylcarboxylate (175 mg) in tetrahycirofuran (2 ml) were added 2-methyl-l-propanol (33.8 mg), triphenylphosphine (159 mg) and diethyl 1,2-diazenedicarboxylate (78 mg) at room temperature and the mixture was stirred at room temperature for 80 hours under nitrogen. The mixture was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel {hexane/ethyl acetate = 8/2) to give a carboxylate product. To a solution of the product in methanol (2 ml) / tetrahydrofuran (1 ml) was added aqueous solution of sodium hydroxide (IN, 0.62 ml) at room temperature and the mixture was stirred at 50°C for 3 hours. The mixture solution was acidified with aqueous hydrochloric acid solution (IN), poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and evaporated under reduced pressure to give 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-isobutoxy-4-biphenylcarboxylic acid (129 mg). (-)ESI-MS (m/z): 616 (M-H)~ Example 1 To a solution of tert-butyl [2-(4-bromophenyl)ethyl]-[(2R)-2-hydroxy-2-phenylethyl]carbamate (280 mg) in 1,2-dimethoxyethane (4 ml) was added methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-thienyl)benzoate (275 mg), tetrakis (triphenylphosphine)palladium (62 mg) and aqueous solution'of sodium carbonate (2M, 0.7 ml), and the mixture was stirred at 80°C for 4 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-phenylethyl]amino]- ethyl]-3-(2-thienyl)-4-biphenylcarboxylate (191 mg). MS (m/z): 558 (M+H) Example 2 The following compounds were obtained according to a similar manner to that of Example 1. (1) tert-Butyl [(2R)-2-hydroxy-2-phenylethyl][2-[3'- isobutyl-4'-[[(methylsulfonyl)amino]carbonyl]-4- biphenylyl]ethyl]carbamate MS (m/z): 593 (M-H)~ (2) tert-Butyl [(2R)-2-hydroxy-2-phenylethyl] [2- [3'- (3- methylbutyl)-4'-[[(methylsulfonyl)amino]carbonyl]-4- biphenylyl]ethyl]carbamate MS (m/z): 607 (M-H)~ (3) tert-Butyl [(IS,2R)-2-hydroxy-l-methyl-2- phenylethyl][2-[3'-isobutyl-4'-[[(methylsulfonyl)- amino]carbonyl]-4-biphenylyl]ethyl]carbamate MS (m/z): 607 (M-H)" (4) Methyl 4'-[2-[ (tert-biitoxycarbonyl) [ (1S,2R) -2-hydroxy- l-methyl-2-phenylethyl]amino]ethyl]-3-(isopropylthio)- 4-biphenylcarboxylate(+)ESI-MS (m/z): 586 (M+Na)+ (5) Methyl 4'-[2-[ (tert-butoxycarbonyl) [(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-3-(isopropylthio)-4- biphenylcarboxylate (+)ESI-MS (m/z): 572 (M+Na)+ Example 3 The following compounds were obtained according to a similar manner to that of Preparation 14. (1) Methyl 4'-[2-[(tert-butoxycarbonyl) [(IS,2R)-2-hydroxy- l-methyl-2-phenylethyl]amino]ethyl]-3-isobutyl-4- biphenylcarboxylate ESI-MS (m/z): 568 (M+Na)+ (2) Methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]~3-isopropoxy-4- biphenylcarboxylate (+) ESI-MS (m/z): 556 (M+Na)+ Example 4 To a solution of methyl 4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(2-thienyl)-4-bipheylcarboxylate (188 mg) in methanol (3.3 ml) was added IN aqueous sodium hydroxide solution (1.0 ml), and the mixture was stirred at 40°C for 3 hours. The solvent was removed by evaporation, and the aqueous solution was acidified with IN aqueous hydrochloride solution and extracted with ethyl acetate (30 ml x 2). The combined organic layers were washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give a benzoic acid product. To a solution of the product in ethyl acetate (1.0 ml) was added 4N hydrogen chloride in ethyl acetate (1.0 ml), and the mixture was stirred at room temperature for 12 hours. The resultant solid was collected by filtration and dried to give 4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(2-thienyl)-4-biphenylcarboxylic acid hydrochloride (139 mg). NMR (DMSO-d6, 5): 2.98-3.23 (6H, m) , 4.94-5.00 (1H, m), 6.21 (1H, br), 7.11-7.23 (2H, m) , 7.36-7.41 (7H, m) , 7.61-7.76 (6H, m), 9.10 (1H, br) MS (m/z): 442 (M-HC1-H)" Example 5 The following compounds were obtained according to a similar manner to that of Example 4. (1) 4' -[2-[[(lS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]- amino]ethyl]-3-isobutyl-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.88 (6H, d, J=6.5Hz), 0.96 (3H, d, J=6.5Hz), 1.79-1.92 (1H, m), 2.92 (2H, d, J=7.0Hz), 3.02-3.10 (2H, m), 3.33-3.52 (3H, m), 5.15 (1H, br), 6.12 (1H, br), 7.26-7.61 (9H, m), 7.71 (2H, d, J=8.0Hz), 7.87 (1H, d, J=8.0Hz) MS (m/z): 432 (M-HC1+H)+ (2) 4'-[2-[ [ (2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- (isopropylamino)-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-d6, 5): 1.23 (6H, d, J=6.2Hz), 2.90-3.40 (6H, m) , 3.82-3.94 (1H, m), 5.00 (1H, dd, J=9.9, 2.7Hz), 6.82 (1H, dd, J=8.3, 1.3Hz), 6.92 (1H, s), 7.27-7.42 (7H, m), 7.66 (2H, d, J=8.1Hz), 7.86 (1H, d, J=8.3Hz), 8.91 (1H, br s), 9.28 (1H, br s) (-)ESI-MS (m/z): 417 (M-H)" (3) 4'-[2-[[(lS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]- amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.96 (3H, d, J=6.7Hz), 1.31 (6H, d, J=7.0Hz), 3.02-3.48 (5H, m) , 3.69-3.84 (1H, m) , 5.20 (1H, s), 6.15 (1H, br s), 2.26-7.52 (8H, m) , 7.61 (1H, d, J=l.lHz), 7.73 (2H, d, J=8.1Hz), 7.91 (1H, d, J=8.1Hz) (-)ESI-MS (m/z): 448 (M-H)" Example 6 To a solution of tert-butyl [(2R)-2-hydroxy-2- phenylethyl][2-[3'-(3-methylbutyl)-4'-[[(methylsulfonyl)-amino]carbonyl]-4-biphenylyl]ethyl]carbamate (380 mg) in ethyl acetate (2.0 ml) was added 4N hydrogen chloride in ethyl acetate (2.0 ml), and the mixture was stirred at room temperature for 12 hours. The resultant solid was collected by filtration and dried to give 4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(3-methylbutyl)-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride (80 mg). NMR (DMSO-d5, 5): 0.91 (6H, d, J=6.2Hz), 1.44-1.57 (3H, m) , 2.77-2.85 (2H, m), 3.04-3.08 (3H, m), 3.20-3.32 (3H, m), 3.37 (3H, s), 4.94-5.00 (1H, m) , 6.22 (1H, br), 7.32-7.42 (7H, m), 7.55-7.60 (3H, m), 7.70 (2H, d, J=8.0Hz), 8.82-9.10 (2H, br) MS (m/z): 507 (M-HC1+H)+ Example 7 The following compounds were obtained according to a similar manner to that of Example 6. (1) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- isobutyl-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMS'0-d6, 5): 0.87 (6H, d, J=6.5Hz), 1.82-1.86 (1H, m), 2.73 (2H, d, J=7.0Hz), 3.02-3.08 (3H, m) , 3.19-3.23 (3H, m), 3.36 (3H, s), 4.95-5.00 (1H, m) , 6.22 (1H, br), 7.32-7.41 (7H, m), 7.53-7.61 (3H, m), 7.70 (2H, d, J=8.0Hz), 8.83 (1H, br), 9.12 (1H, br) MS (m/z): 493 (M-HC1+H)+ (2) 4' -[2-[[(IS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]- amino]ethyl]-3-isobutyl-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMS0-d6, 6): 0.87 (6H, d, J=6.5Hz), 0.99 (3H, d, J=6.5Hz), 1.81-1.88 (1H, m), 2.74 (2H, d, J=7.0Hz), 3.05-3.13 (2H, m), 3.33-3.54 (3H, m) , 3.37 (3H, s), 5.19 (1H, br), 6.14-6.16 (1H, br)r 7.28-7.44 (7H, m) , 7.52-7.63 (3H, m), 7.71 (2H, d, J=8.0Hz), 8.88 (2H, br) MS (m/z): 507 (M-HC1-H)" (3) 4'-[2- [ [ (2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- (isopropylthio)-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.26 (6H, d, J=6.6Hz), 3.00-3.30 (6H, m), 3.65 (1H, m), 4.95-5.00 (1H, m) , 6.22 (1H, d, J=3.7Hz), 7.30-7.42 (7H, m) , 7.61 (2H, s), 7.70-7.74 (3H, m) (-)ESI-MS (m/z): 511 (M-H)~ Example 8 To a solution of methyl 4'-[2-(benzylamino)ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (250 mg) in ethanol (15 ml) was added (R) - ( + ) -styreneoxide (142 |al) at room temperature, and the mixture was stirred under reflux for 48 hours. The mixture was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'-[2-[benzyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (251 mg). (+)ESI-MS (m/z): 523 (M+H)+ Example 9 To methyl 4'-[2-[benzyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (240 mg) was added 4N hydrogen chloride solution in ethyl acetate (287 jil) and evaporated under reduced pressure. The suspension of the obtained hydrochloride in methanol (2.5 ml) and tetrahydrofuran (2,5 ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 24 mg) under hydrogen atmosphere for 2.5 hours. The catalyst was filtered off and the filtrate was evaporated under reduced pressure. To a solution of the residue in tetrahydrofuran (2.5 ml) and water (2.5 ml) was added di-tert-butyl dicarbonate (110. mg) tetrahydrofuran solution at 0°C and the mixture was stirred at room temperature for 30 minutes. The mixture was poured into water, extracted with ethyl acetate, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'- [2-[ (tert-butoxycarbonyl)[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylamino)-4-biphenylcarboxylate (170 mg). (+)ESI-MS (m/z): 555 (M+Na)+ Example 10 To a solution of methyl 4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-hydroxy-2-pyhenylethyl]amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylate (864 mg) in methanol (16 ml) was added aqueous solution of sodium hydroxide (IN, 4.71 ml) at room temperature and the mixture was stirred at 50°C for 2.5 hours. The mixture solution was acidified with IN aqueous hydrochloric acid solution, poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give 4'-[2- [ (tert-butoxycarbonyl) [(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylic acid (695 mg). (-)ESI-MS (m/z): 534 (M-H)~ Example 11 To a solution of methyl 4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-isopropoxy-4- biphenylcarboxylate (1.40 g) in methanol (15 ml)/tetrahydrofuran (6 ml) was added aqueous solution of sodium hydroxide (IN, 7.8 9 ml) at room temperature and the mixture was stirred at room temperature for 18 hours. The mixture solution was acidified with aqueous hydrochloric acid solution (IN), poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 5/5) to give 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-phenylethyl]amino]-ethyl]-3-isopropoxy-4-biphenylcarboxylic acid (1.40 g). (-)ESI-MS (m/z): 518 (M-H)" Example 12 To a solution of 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylthio)-4-biphenycarboxylic acid (131 mg) in N,N-dimethylformamide (2.6 ml) were added methanesulfonamide (24.9 mg), 4-(dimethylamino)pyridine (43.7 mg) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (91.4 mg) at room temperature and the mixture was stirred at the same temperature for 72 hours. The mixture was poured into aqueous hydrochloric acid solution (0.3N) and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/3) to give tert-butyl [(2R)-2-hydroxy-2-phenylethyl][2-[3'-(isopropylthio)-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl]-carbamate (10 mg). (+)ESI-MS (m/z): 635 (M+Na)+ Example 13 The following compound was obtained according to a similar manner to that of Example 12, tert-Butyl [(2R)-2-hydroxy-2-phenylethyl][2-[3'-isopropoxy-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl]carbamate (+)ESI-MS (m/z): 619 (M+Na)+ Example 14 To a solution of tert-butyl [2-[3'-(cyclohexyloxy)-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]carbamate (89 mg) in 1,4-dioxane (2 ml) was added 4N hydrogen chloride solution in 1,4-dioxane (4 ml) at room temperature and the mixture was stirred at the same temperature for 2 hours. The mixture was evaporated under reduced pressure to give 3-(cyclohexyloxy)-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride (76 mg). NMR (DMS'O-dg, 5): 1.32-1.81 (8H, m) , 1.89-2.02 (2H, m) , 2.98-3.30 (6H, m), 3.38 (3H, s), 4.75-4.87 (1H, m) , 4.98-5.03 (1H, in), 6.23 (1H, d, J=3.8Hz), 7.31-7.. 42 (9H, m) , 7.71-7.80 (3H, m) (+)ESI-MS (m/z): 537 (M+H)+ Example 15 The following compound was obtained according to a similar manner to that of Example 14. 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutoxy-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.05 (6H, d, J=6.6Hz), 2.04-2.17 (1H, m), 2.99-3.23 (6H, m), 3.37 (3H, s) , 4.03 (2H, d, J=6.2Hz), 4.98-5.03 (1H, m), 6.23 (1H, d, J=3.9Hz), 7.32-7.41 (9H, m) , 7.70-7.78 (3H, m) (+)ESI-MS (m/z): 511 (M+H)+ Example 16 The following compounds were obtained according to a similar manner to that of Preparation 14 followed by a similar manner to that of Example 4. (1) 3-Cyclopentyl-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]- amino]ethyl]-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d5, 5): 1.5-2.2 (8H, m), 2.9-3.7 (6H, m) , 3.82 (1H, m), 4.98 (1H, m) , 6.20 (1H, m), 7.1-7.8 (12H, m) MS (m/z): 430 (M+H) (2) 3-Cyclopentyl-4'-[2-[[(IS,2R)-2-hydroxy-l-methyl-2- phenylethyl]amino]ethyl]-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.94 (3H, d, J=6.8Hz), 1.5-2.2 (8H, m), 3.0-3.7 (5H, m), 3.82 (1H, m) , 5.19 (1H, m), 6.15 (1H, m), 7.1-7.8 (12H, m) MS (m/z): 444 (M+H) (3) 4'-[2-[[(lS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]- amino]ethyl]-3-isopropoxy-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.97 (3H, d, J=6.6Hz), 1.32 (6H, d, J=6.0Hz), 3.0-3.6 (5H, m), 4.82 (1H, m), 5.21 (1H, m), 6.15 (1H, m), 7.1-7.5 (9H, m), 7.7-7.9 (3H, m) MS (m/z): 434 (M+H) (4) 4'-[(2S)-3-Hydroxy-2-[[(2R)-2-hydroxy-2-phenylethyl]- amino]propyl]-3-isopropoxy-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 6): 1.31 (6H, d, J=6Hz), 2.8-3.5 (7H, m) , 4.82 (1H, m), 5.00 (1H, m), 5.41 (1H, m), 6.23 (1H, m), 7.2-7.8 (12H, m) MS (m/z): 450 (M+H) (5) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]-1- methylethyl]-3-isopropoxy-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 1.31 (6H, d, J=6.0Hz), 1.35 (3H, d, J=6.6Hz), 2.8-3.5 (5H, m), 4.82 (1H, m), 5.02 (1H, m), 6.17 (1H, m), 7.2-7.5 (9H, m), 7.6-7.9 (3H, m) MS (m/z): 434 (M+H) Example 17 The following compounds were obtained according to a similar manner to that of Preparation 14 followed by a similar manner to that of Example 6. (1) 3-(Cyclohexyloxy)-4'-[2-[[(IS,2R)-2-hydroxy-l-methyl-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 0.97 (3H, d, J=6.6Hz), 1.3-2.1 (10H, m) , 3.0-3.6 (5H, m), 4.82 (1H, m), 5.20 (1H, m), 6.16 (1H, m) , 7.2-7.5 (9H, m) , 7.7-7.9 (3'H, m) MS (m/z): 551 (M+H) (2) 3-(Cyclohexyloxy)-4'-[2-[[(2R)-2-hydroxy-2-(3- pyridyl)ethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 5): 1.2-2.1 (10H, m), 3.0-3.6 (5H, m) , 4.81 (1H, m), 5.20 (1H, m), 7.2-7.4 (4H, m), 7.7-7.9 (3H, m), 7.9-8.0 (1H, m), 8.46 (1H, m), 8.82-8.89 (2H, m) MS (m/z): 538 (M+H) Example 18 To a solution of tert-butyl [(2R)-2-hydroxy-2-phenylethyl][2-[3'-(isopropoxy)-4'-[[(methylsulfonyl)amino]- carbonyl]-4-biphenylyl]ethyl]carbamate (65 mg) in 1,4-dioxane (2 ml) was added hydrochloric acid 1,4-dioxane solution (4N, 4 ml) at room temperature and the mixture was stirred at the same temperature for 2.5 hours. The mixture was evaporated under reduced pressure to give 4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-isopropoxy-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride (38 mg) . NMR (DMSO-d6, 5): 1.37 (6H, d, J=5.7Hz), 3.06-3.25 (6H, m), 3.38 (3H, s), 4.97-5.00 (2H, m), 6.23 (1H, br s), 7.28-7.48 (9H, m) , 7.72-7.79 (3H, m) (+)ESI-MS (m/z): 497 (M+H)+ Example 19 To a solution of 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-isopropoxy-4-biphenylcarboxylic acid (224 mg) in N,N-dimethylformamide (2 ml) was added 1,1'—carbonyldiimidazole (72 mg) at room temperature and the mixture was stirred at the same temperature for 1 hour. 1-Pentanesulfonamide (67 mg) and 1,8-diazabicyclo[5-4.0]-7-undecene (0.067 ml) were added to the mixture at room temperature. The mixture was stirred at 70°C for 4 hours. After cooling down to room temperature, the mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid solution (0.5N) and brine, dried over sodium sulfate and evaporated under reduced pressure to give residue (403 mg). To a solution of the above residue in methanol (2 ml) was added 4-methylbenzenesulfonic acid at room temperature and the mixture was stirred at the same temperature for 2 days. The mixture was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 7/3) to give tert-butyl [ (2R)-2-hydroxy-2-phenylethyl] [2-[3'-isopropoxy-4'-[[(pentylsulfonyl)amino]carbonyl]-4- biphenylyl]ethyl]carbamate (179 mg). (+)ESI-MS (m/z): 675 (M+Na)+ Example 20 To a solution of tert-butyl [(2R)-2-hydroxy-2-phenylethyl][2-[3'-isopropoxy-4'-[[(pentylsulfonyl)amino]-carbonyl]-4-biphenylyl]ethyl]carbamate (170 mg) in ethyl acetate (2 ml) was added hydrochloric acid ethyl acetate solution (4N, 4 ml) at room temperature and the mixture was stirred at the same temperature overnight. The mixture was filtered to collect the precipitate and the precipitate was washed with ethyl acetate. The precipitate was dried under reduced pressure to give 4'- [2- [ [(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-isopropoxy-N-(pentylsulfonyl)-4-biphenylcarboxamide hydrochloride (106 mg). NMR (DMSOd6, 5): 0.87 (3H, t, J=7.0Hz), 1.21-1.46 (4H, m), 1.36 (6H, d, J=6.0Hz), 1.67-1.81 (2H, m) , 2.99-3.29 (6H, m) , 3.51 (2H, t, J=7.7Hz), 4.91-5.05 (2H, m), 6.23 (1H, d, J=4.0Hz), 7.32-7.43 (9H, m), 7.67-7.76 (3H, m) (+)ESI-MS (m/z): 553 (M+H)+ Example 21 The following compounds were obtained according to a similar manner to that of Example 19. (1) tert-Butyl [(2R)-2-hydroxy-2-phenylethyl][2-[4'- [[(isobutylsulfonyl)amino]carbonyl]-3' -isopropoxy-4-biphenylyl]ethyl]carbamate (+)ESI-MS (m/z): 661 (M+Na)+ (2) tert-Butyl [(2R)-2-hydroxy-2-phenylethyl] [2- [3'- isopropoxy-4'-[[[(3-methylbutyl)sulfonyl]amino]- carbonyl]-4-biphenylyl]ethyl]carbamate (+)ESI-MS (m/z): 675 (M+Na)+ (3) tert-Butyl [2- [4'-[[[ (cyclohexylmethyl)sulfonyl]- amino]carbonyl]-3'-isopropoxy-4-biphenylyl]ethyl] [ (2R)- 2-hydroxy-2-phenylethyl]carbamate (+JESI-MS (m/z): 701 (M+Na)+ (4) tert-Butyl [2-[4'-[[(benzylsulfonyl) amino]carbonyl]-3'- (cyclohexyloxy)-4-biphenylyl]ethyl][(2R)-2-hydroxy-2- phenylethyl]carbamate (+)ESI-MS (m/z): 735 (M+Na)+ Example 22 The following compounds were obtained according to a similar manner to that of Example 6. (1) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-N- (isobutylsulfonyl)-3-isopropoxy-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.06 (6H, d, J=7.0Hz), 1.36 (6H, d, J=6.0Hz), 2.10-2.30 (1H, m), 2.99-3.27 (6H, m), 3.44 (2H, d, J=6.6Hz), 4.92-5.05 (2H, m), 6.24 (1H, d, J=4.0Hz), 7.32-7.43 (9H, m), 7.68-7.76 (3H, m) (+)ESI-MS (m/z): 539 (M+H)+ (2) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- isopropoxy-N-[(3-methylbutyl)sulfonyl]-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 0.90 (6H, d, J=6.0Hz), 1.36 (6H, d, J=6.0Hz), 1.55-1.78 (3H, m), 2.90-3.27 (6H, m) , 3.48-3.55 (2H, m) , 4.91-5.05 (2H, m), 6.23 (1H, d, J=3.5Hz), 7.32-7.43 (9H, m), 7.66-7.75 (3H, m) (+)ESI-MS (m/z): 553 (M+H)+ (3) N-[(Cyclohexylmethyl)sulfonyl]-4'-[2-[[(2R)-2-hydroxy- 2-phenylethyl]amino]ethyl]-3-isopropoxy-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.09-1.31 (5H, m), 1.36 (6H, d, J=6.0Hz), 1.53-1.73 (3H, m) , 1.80-1.97 (3H, m) , 3.02-3.27 (6H, m), 3.45 (2H, d, J=6.0Hz), 4.92-5.04 (2H, m), 6.23 (1H, d, J=3.5Hz), 7.31-7.43 (9H, m) , 7.68-7.76 (3H, m) (+)ESI-MS (m/z): 579 (M+H)+ Example 2 3 The following compound was obtained according to a similar manner to that of Example 18. N-(Benzylsulfonyl)-3-(cyclohexyloxy)-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6/ 5): 1.14-1.69 (8H, m) , 1.74-1.92 (2H, m) , 2.97-3.29 (6H, m), 4.68-4.81 (1H, m) , 4.87 (2H, s), 4.95-5.06 (1H, m), 6.23 (1H, d, J=3.8Hz), 7.28-7.46 (14H, m), 7.67-7.81 (3H, m) (+)ESI-MS (m/z): 613 (M+H)+ Preparation 18 To a mixture of (1R)-2-amino-l-(3-pyridyl)ethanol dihydrochloride (2 60 g), (4-bromophenyl)acetic acid (27 8 g), 1-hydroxybenzotriazole (175 g) and 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (248 g) in N,N-dimethylformamide (1.3 I ) was added triethylamine (361 I ) at ambient temperature for 1 hour. The mixture was stirred at room temperature overnight. To the mixture was added water (1.3 I ) . The mixture was poured into water (1.6 I ) and basified with 24% aqueous sodium hydroxide solution. The mixture was stirred at room temperature for 5 hours. The precipitate was collected by filtration, washed with water and dried in vacuo to give 2-(4-bromophenyl)-N-[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]acetamide (335 g). (-f)ESI-MS (m/z) : 335 (M+H) + Preparation 19 To a mixture of 2-(4-bromophenyl)-N-[(2R)-2-hydroxy-2-(3-pyridyl) ethyl] acetamicie (160 g) in tetrahycirofuran (1.6 I ) was added dropwise 2M borane-dimethylsulfide complex in tetrahydrofuran (716 ml) below 0°C over 5 hours. The mixture was warmed up to 60°C and stirred at the same temperature for 3 hours. The reaction mixture was cooled in ice bath (below 5°C) . To the cooled reaction mixture were added methanol and cone, hydrochloric acid (hydrogen gas was evolved). The mixture was heated and stirred at 60°C for 1 hour, stood overnight at ambient temperature. The mixture was concentrated in vacuo and water was removed as azeotrope with butanol (480 ml). The concentrate was pulverized with isopropyl ether (1.5i). The precipitate was collected by filtration, washed with isopropyl ether and dried in vacuo to give (1R)-2- [ [2-(4-bromophenyl)ethyl]amino]-1-(3-pyridyl)ethanol dihydrochloride (226 g). (+)ESI-MS (m/z): 321 (M+H)+ Preparation 20 (1R)-2- [ [2- (4-Bromophenyl)ethyl]amino]-1- (3-pyridyl)ethanol dihydrochloride (188 g) was dissolved in water (750 ml) and tetrahydrofuran (750 ml) was added. pH of the solution was adjusted to 7.5 with 5N aqueous sodium hydroxide solution (90 ml). To the solution was added di-tert-butyl dicarbonate (115 g) in tetrahydrofuran (100 ml) dropwise at room temperature over 18 minutes, keeping the pH at 7.5-7.6 with aqueous sodium hydrodxide solution. The solution was stirred at room temperature for 1 hour. The mixture was partitioned between ethyl acetate (1.5 I ) and water (1.5 I). The organic layer was separated and washed with water (1.5 t ) and brine (1.5 I), dried over sodium sulfate, and evaporated under reduced pressure to give tert- butyl [2-(4-bromophenyl)ethyl] [(2R)-2-hydroxy-2- (3-pyridyl)ethyl]carbamate (187 g). (+JESI-MS (m/z): 421 (M+H)+ Preparation 21 A mixture of l-iodo-3-methylbutane (12 g) and potassium thiocyanate (5.9 g) in acetone (110 ml) was refluxed for 4 hours. After precipitate was filtered off, the filtrate was evaporated in vacuo. Water was added to the residue followed by extraction with chloroform. The extract was dried over magnesium sulfate and evaporated under reduced pressure to give the thiocyanate (8.3 g). A solution of above thiocyanate was bubbled with chlorine gas for 1 hour under ice-cooling (below 0°C) with stirring followed by extraction with diisopropyl ether. After extract was dried over sodium sulfate, the solvent was evaporated in vacuo to give sulfonyl chloride (9.0 g). To a 28% ammonium hydroxide (50 ml) was added dropwise crude sulfonyl chloride in dichloromethane (15 ml) over 20 minutes at approximately 0°C. The reaction mixture was stirred vigorously overnight at ambient temperature. The phases were separated. The aqueous phase was extracted with chloroform/methanol (5/1). The combined organic extracts were washed with half-brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform/methanol=95/5) to give 3-methyl-1-butanesulfonamide (4.3 g). (+)ESI-MS (m/z): 174 (M+Na)+ Preparation 22 The following compound was obtained according to a similar manner to that of Preparation 21. 1- Cyclohexylmethanesulfonamide (+)ESI-MS (m/z): 200 (M+Na)+ Preparation 23 To a mixture of methyl 4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-phenyl-2-(tertrahydro-2H-pyran-2-yloxy)ethyl]amino]-ethyl]-3-hydroxy-4-biphenylcarboxylate (173 mg) in N,N-dimethylformamide (2 ml) were added potassium carbonate (49 mg) and iodomethane (0-03 ml) at room temperature and the mixture was stirred at room temperature overnight. The mixture was poured into water and extracted with ethyl acetate. The organic layer was separated, washed with aqueous hydrochloric acid solution (0.1N) and brine, dried over sodium sulfate and evaporated under reduced pressure. To a mixture of the above residue (170 mg) in methanol (1.5 ml)/tetrahydrofuran (1 ml) was added aqueous sodium hydroxide solution (IN, 0,86 ml) at room temperature and the mixture was stirred at 50°C for 3 hours. The mixture was acidified with aqueous hydrochloric acid solution (IN, 0.87 ml), poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and evaporated under reduced pressure to give 4'-[2-[ (tert-butoxycarbonyl) [(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-methoxy-4-biphenylcarboxylic acid (159 mg). (-)ESI-MS (m/z): 574 (M-H)~ Preparation 24 To a ammonium hydroxide (28%, 80 ml) was added a solution of 4-bromo-2-fluorobenzenesulfonyl chloride (10 g) in dichloromethane (80 ml) dropwise for 1 hour at approximately 0°C. The reaction mixture was stirred vigorously for an additional 2 hours at the same temperature. The phases were separated. The aqueous phase was washed with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give 4-bromo-2-fluorobenzenesulfonamide (8.0 g). ( + )ESI-MS (m/z) : 276 (M+Na) + Preparation 25 To a suspension of sodium hydride (60%, 0.65 g) in N,N-dimethylformamide (22 ml) was added a solution of cyclohexanol (2.7 ml) in N,N-dimethylformamide (6 ml) for 30 minutes at ambient temperature. The suspension was stirred for 30 minutes at room temperature. A solution of 4-bromo-2-fluorobenzenesulfonamide (3 g) in N,N-dimethylformamide (13 ml) was added dropwise over 30 minutes at ambient temperature. The suspension was stirred at room temperature for 1 hour and at 60°C for 2 hours. The suspension was poured into a mixture of ice (35 ml) and aqueous hydrochloric acid solution (IN, 35 ml), and the mixture was stirred at room temperature for 1 hour. The mixture was filtered to collect precipitate and the precipitate was washed with water and hexane. The precipitate was dried under reduced pressure to give 4-bromo-2-(clohexyloxy)-benzenesulfonamide (3.6 g). (+)ESI-MS (m/z): 356 (M+Na)+ Preparation 26 To a solution of 4-bromo-2~(cyclohexyloxy)-benzenesulfonamide (3.6 g) in 1,4-dioxane (35 ml) were added (triphenylphosphine)palladium(II) (528 mg) and potassium acetate (3.16 g), and the mixture was stirred at 95°C for 2 hours under nitrogen atmosphere. After cooling down to room temperature, the mixture was poured into brine and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated under reduced pressure to give residue (6.4 g). To a mixture of the above residue in ethyl acetate (50 ml) and water (50 ml) were added ammonium acetate (1.8 g) and sodium periodate (5.0 g). The mixture was stirred at room temperature overnight. Precipitate was filtered off and the precipitate was washed with ethyl acetate/methanol (9/1). The filtrate was washed with aqueous hydrochloric acid solution (0.5N) and brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform/methanol = 95/5) to give [4-(aminosulfonyl)-3-(cyclohexyloxy)phenyl]boronic acid (2.5 g). (+)ESI-MS (m/z): 322 (M+Na)+ Preparation 27 To a solution of methyl 3-(isopropylthio)-4'-[2-methyl-2-[(trifluoroacetyl)amino]propyl] -4-biphenylcarboxylate (810 mg) in ethanol was added sodium hydroxide aqueous solution (1M, 9 ml) at room temperature and stirred under reflux for 4 hours. The resultant mixture was evaporated. The residue was dissolved with hydrogen chloride solution in ethanol (5.5M, 12 ml) and stirred at room temperature overnight. The resultant mixture was evaporated and dried to give ethyl 4' -(2-amino-2-methylpropyl)-3-(isopropylthio)-4-biphenylcarboxylate (384 mg). (+)ESI-MS (m/z): 372 (M+H)+ Preparation 28 To a solution of 4-bromo-2-chlorobenzoic acid (2 g), copper bromide(I) (122 mg) and potassium carbonate (2.35 g) in N,N-dimethylformamide (20 ml) was added cyclohexylamine (972 \xl) at room temperature and stirred at 150°C overnight. The mixture was poured into water, acidified with concentrated hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give a aniline product. To a suspension of the aniline product in methanol (6.5 ml) was added concentrated sulfuric acid (650 \il) at room temperature and stirred under reflux for 1 week. The mixture was poured into saturated sodium bicarbonate aqueous solution and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated to give methyl 4-bromo-2-(cyclohexylamino)benzoate (549 mg). (+)ESI-MS (m/z): 312 (M+H)+ Preparation 29 The following compound was obtained according to a similar manner to that of Preparation 10 followed by a similar manner to that of Preparation 11. Methyl 4'-[2-(benzylamino)ethyl]-3-(cyclohexylamino)-4-biphenylcarboxylate (+)ESI-MS (m/z): 443 (M+H)+ Preparation 30 To a solution of methyl 4'-[2-[benzyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-nitro-4-biphenylcarboxylate (2.31 g) in methylene chloride (35 ml) were added dihydropyran (1.24 ml) and pyridinium p-toluenesulfonate (1.36 mg) and stirred overnight at room temperature. The mixture was poured into saturated sodium bicarbonate aqueous solution and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate aqueous solution twice and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'-[2-[benzyl [ (2R) -2-phenyl-2- (tetrahydro-2H-pyra.n-2-yloxy) ethyl] -amino]ethyl]-3-nitro-4-biphenylcarboxylate (1.48 g). (+)ESI-MS (m/z): 595 (M+H)+ Preparation 31 To a solution of methyl 4'[2-[benzyl[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-nitro-4-biphenylcarboxylate (1.44 g) in ethanol (30 ml) and water (10 ml) were added iron (406 mg) and ammonium chloride (65 mg) and stirred under reflux for 1.5 hours. The mixture was filtrated through Celite pad and evaporated. The residue was dissolved with ethyl acetate, chloroform and methanol, washed with saturated sodium bicarbonate aqueous solution and brine, dried over magnesium sulfate and evaporated to give methyl 3-amino-4'-[2-[benzyl[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-4-biphenylcarboxylate (1.18 g). (+)ESI-MS (m/z): 565 (M+H)+ Preparation 32 To a solution of methyl 3-amino-4'-[2-[benzyl[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-4-biphenylcarboxylate (532 mg) in pyridine (600 \il) was added acetic anhydride (400 \xl) and stirred overnight at room temperature. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with saturated ammonium chloride aqueous solution and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 3-(acetylamino)-4'- [2- [benzyl[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-4-biphenylcarboxylate (381 mg). (+)ESI-MS (m/z): 607 (M+H)+ Preparation 33 To a solution of (, 5.46 (1H, dd, J=2.3r 7Hz) , 7.23-7.34 (7H, m) , 7.47-7.51 (2H, m), 7.7 (2H, d, J=4Hz), 7.98 (1H, d, J=4Hz) (7) Methyl 4'- [2-[ (tert-butoxycarbonyl) [(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-3-(ethylthio)-4- biphenylcarboxylate (+)ESI-MS (m/z): 558 (M+Na)+ (8) tert-Butyl [2-[4'-formyl-3'-[isopropyl(methyl)amino]-4-biphenylyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]carbamate MS (m/z): 517 (M+H)+ Example 32 The following compound was obtained according to a similar manner to that of Example 8. Methyl 4'-[2-[benzyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-nitro-4-biphenylcarboxylate (+)ESI-MS (m/z): 511 (M+H)+ Example 33 The following compounds were obtained according to a similar manner to that of Example 8 followed by a similar manner to that of Example 9 and then a similar manner to that of Example 4. (1) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-2- isobutyl-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.68 (6H, d, J=6.6Hz), 1.54-1.68 (1H, m), 2.5 (2H, d, J=7.0Hz), 3.0-3.3 (6H, m), 4.97-5.01 (1H, m), 6.21 (1H, br), 7.23-7.42 (10H, m), 7.78-7.84 (2H, m) MS (m/z): 416 (M-HC1-H)" (2) 4'-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]- ethyl]-2-isobutyl-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.68 (6H, d, J=6.6Hz), 1.54-1.68 (1H, m) , 2.5 (2H, d, J=7.0Hz), 3.0-3.3 (6H, m), 4.99-5.03 (1H, m), 6.23 (1H, br) , 7.23-7.48 (10H, m), 7.78-7.84 (2H, m) MS (m/z): 450 (M-HC1-H)" (3) 2-Butyl-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]- ethyl]-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.75 (3H, t, J=7.1Hz), 1.1-1.2 (2H, m) , 1.3-1.4 (2H, m), 2.6 (2H, t, J=7.2Hz), 3.0-3.3 (6H, m) , 4.95-5.00 (1H, m), 6.21 (iH, br), 7.23-7.42 (10H, m), 7.78-7.90 (2H, m) MS (m/z): 416 (M-HC1-H)~ (4) 2-Butyl-4'-[2-[[(2R)-2-(3-chlorophenyl)-2- hydroxyethyl]amino]ethyl]-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 0.75 (3H, t, J=7.1Hz), 1.1-1.2 (2H, m), 1.3-1.5 (2H, m), 2.6 (2H, t, J=7.2Hz), 3.0-3.3 (6H, m), 4.99-5.03 (IH, m), 6.35 (IH, br), 7.23-7.48 (10H, m), 7.78-7.89 (2H, m) MS (m/z): 450 (M-HC1-H)" (5) 3-(Cyclohexylamino)-4'-[2-[[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-d6, 5): 1.14-1.99 (10H, m) , 2.95-3.32 (6H, m), 3.61 (IH, m), 5.00 (IH, dd, J=2.8, 10Hz), 6.79 (IH, dd, J=1.2, 8.3Hz), 6.91 (IH, s), 7.3-7.42 (7H, m), 7.65 (2H, d, J=8.2Hz), 8.91 (IH, br s), 9.26 (IH, br s) (-)ESI-MS (m/z): 457 (M-H)" Example 34 The following compounds were obtained according to a similar manner to that of Example 9. (1) Methyl 3-amino-4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-4- biphenylcarboxylate (+JESI-MS (m/z): 513 (M+Na)+ (2) Methyl 3-(acetylamino)-4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-4-biphenylcarboxylate (+)ESI-MS (m/z): 555 (M+Na)+ Example 35 The following compounds were obtained according to a similar manner to that of Example 1 followed by a similar manner to that of Example 6. (1) 4' -[2-[ [ (2R)-2-Hydroxy-2-phenylethyl] amino] ethyl]-3- (isobutylthio)-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.01 (6H, d, J=6.6Hz), 1.76-1.9 (1H, m), 2.94 (2H, d, J=6.7Hz), 3.06-3.21 (6H, m), 3.37 (3H, s), 4.97-5.02 (1H, m) , 6.23 (1H, d, J=3.8Hz), 7.28-7.42 (7H, m), 7.53 (1H, dd, J=1.2, 8.4Hz), 7.61-7.65 (2H, m), 7.72 (2H, d, J=8.2Hz), 8.89 (1H, br s), 9.2 (1H, br s), 12.20 (1H, br s) (-)ESI-MS (m/z): 525 (M-H) ~ (2) 3-(Cyclohexylthio)-4'-[2-[[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMS0-d6, 5): 1.14-1.99 (10H, m), 3.04-3.42 (6H, m) , 3.36 (3H, s), 4.94-4.99 (1H, m) , 6.22 (1H, d, J=3.8Hz), 7.28-7.42 (7H, m) , 7.6 (2H, s), 7.69 (1H, s), 7.73 (2H, s), 8.85 (1H, br s), 9.04 (1H, br s), 12.19 (1H, br s) (-)ESI-MS (m/z): 551 (M-H)" (3) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-N- (methylsulfonyl)-3-(propylthio)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.00 (3H, t, J=7.3Hz), 1.57-1.68 (2H, m), 3.03 (2H, t, J=7.2Hz), 3-3.34 (6H, m) , 3.37 (3H, s), 4.96-5.01 (1H, m) , 6.23 (1H, d, J=3.8Hz), 7.3-7.42 (7H, m) , 7.54 (1H, d, J=8.lHz), 7.63-7.67 (2H, m), 7.73 (2H, d, J=8.2Hz) (-)ESI-MS (m/z): 511 (M-H)~ (4) 3-(Ethylthio)-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]- amino]ethyl]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMS0-d6, 5): 1.26 (3H, t, J=7.3Hz), 3.07 (2H, q, J=7.3Hz), 3.02-3.33 (6H, m), 3.36 (3H, s), 4.94-4.99 (1H, m), 6.22 (1H, d, J=3.8Hz), 7.28-7.42 (7H, m) , 7.53 (1H, dd, J=1.5, 8.1Hz), 7.63-7.68 (2H, m) , 7.73 (2H, d, J=8.2Hz), 8.85 (1H, br s), 9.07 (1H, br s) (-)ESI-MS (m/z): 497 (M-H)" (5) 3-(Cyclopentylthio)-4'-[2-[[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.52-1.77 (6H, m), 1.99-2.16 (2H, m), 3.06-3.32 (6H, m), 3.37 (3H, s), 3.84-3.93 (1H, m), 4.97-5.02 (1H, m), 6.24 (1H, d, J=3.5Hz), 7.28-7.42 (7H, m), 7.55 (1H, dd, J=1.3, 8.2Hz), 7.64 (1H, d, J=8.1Hz), 7.7-7.74 (3H, m), 8.9 (1H, br s), 9.26 (1H, br s) (-)ESI-MS (m/z): 537 (M-H)" (6) 3-(Cyclohexylamino)-4'-[2-[[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide dihydrochloride NMR (DMS0-d6, 5): 1.14-1.66 (8H, m) , 1.91-1.99 (2H, m), 3.08-3.37 (6H, m), 3.37 (3H, s), 3.55-3.72 (1H, m), 5 (1H, d, J=7.6Hz), 6.83 (1H, d, J=8.2Hz), 6.92 (1H, s), 7.32-7.42 (7H, m), 7.68 (2H, d, J=8Hz), 7.82 (1H, d, J=8.4Hz), 8.93 (1H> br s)., 9.29 (1H, br s) (+)ESI-MS (m/z): 536 (M+H)+ (7) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- (isopropylamino)-N- (methylsulfonyl)-4- biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 5): 1.24 (6H, d, J=6.2Hz), 2.98-3.32 (6H, m) , 3.37 (3H, s) , 3.89-3.98 (1H, m) , 5.51 (1H, d, J=4.4Hz), 6.86 (1H, d, J=8.4Hz), 6.97 (1H, s), 7.3-7.42 (7H, m) , 7.7 (2H, d, J=8.1Hz), 7.83 (1H, d, J=8.4Hz), 8.94 (1H, br s), 9.35 (1H, br s) (-)ESI-MS (m/z): 494 (M-H)" (8) 4'-[2-[[(IS,2R)-2-Hydroxy-l-methyl-2-phenylethyl]- amino]ethyl]-3-(isopropylthio)-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 0.97 (3H, d, J=6.6Hz), 1.26 (6H,. d, J=6.6Hz), 3.11-3.45 (5H, m), 3.35 (3H, s), 3.6-3.73 (1H, m), 5.22 (1H, br s), 6.16 (1H, d, J=4.2Hz), 7.24-7.46 (7H, m), 7.62 (2H, s), 7.72-7.76 (3H, m), 9.00 (2H, br s), 12.21 (1H, br s) (-)ESI-MS (m/z): 525 (M-H)" Example 3 6 The following compound was obtained according to a similar manner to that of Example 1. tert-Butyl [(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl][2-[3'-isobutyl-4'-[[(methylsulfonyl)amino]-carbonyl]-4-biphenylyl]ethyl]carbamate MS (m/z): 628 (M-H)" Example 37 The following compounds were obtained according to a similar manner to that of Example 6. (1) 4'-[2-[[(2R)-2-(6-Chloro-3-pyridyl)-2-hydroxyethyl]- amino]ethoxy]-3-(cyclohexyloxy)-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.3-1.8 (8H, m) , 1.9-2.0 (2H, m) , 3.2-3.5 (4H, m), 3.4 (3H, s), 4.4 (2H, br) , 4.8- 4.9 (1H, m) , 5.1-5.2 (1H, m), 7.12 (2H, d, J=8.8Hz), 7.3-7.4 (2H, m), 7.58 (1H, d, J=8.2Hz), 7.7-7.9 (4H, m), 8.46 (1H, d, J=2.3Hz), 9.1 (2H, br) MS (m/z): 586 (M-HC1-H)" (2) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3- isopropoxy-N-(pentylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMS0-d6, 5): 0.87 (3H, t, J=7.0Hz), 1.21-1.46 (4H, m), 1.36 (6H, d, J=6.0Hz), 1.67-1.81 (2H, m), 2.99-3.29 (6H, m), 3.51 (2H, t, J=7.7Hz), 4.91-5.05 (2H, m), 6.23 (1H, d, J=4.0Hz), 7.32-7.43 (9H, m), 7.67-7.76 (3H, m) (+1ESI-MS (m/z): 553 (M+H)+ (3) 3-Ethoxy-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]- ethoxy]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.42 (3H, t, J=7.0Hz), 3.08-3.29 (2H, m), 3.37 (3H, s), 3.44-3.47 (2H, m), 4.30 (2H, q, J=7.0Hz), 4.36-4.40 (1H, m) , 6.22 (1H, d, J=4.0Hz), 7.11 (2H, d, J=8.4Hz), 7.31-7.43 (7H, m), 7.73 (1H, d, J=8.4Hz), 7.77 (2H, d, J=8.4Hz), 9.18 (3H, br) (-)ESI-MS (m/z): 497 (M-H)" (4) 4'-[3- [ [(2R)-2-Hydroxy-2-phenylethyl]amino]propyl]-3-isopropoxy-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 6): 1.38 (6H, d, J=5.60Hz), 1.88-2.18 (2H, m) , 2.72 (2H, t, J=7.0Hz), 2.87-3.23 (4H, m), 3.38 (3H, s), 4.87-5.08 (2H, m), 6.18 (1H, d, J=3.40Hz), 7.26-7.45 (9H, m), 7.66-7.83 (3H, m) (-)ESI-MS (m/z): 509 (M-H)" 5) 3-(Cyclohexyloxy)-4'-[3-[[(2R)-2-hydroxy-2- phenylethyl]amino]propyl]-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.26-1.83 (8H, m), 1.88-2.13 (4H, m) , 2.72 (2H, t, J=7.0Hz), 2.88-3.22 (4H, m), 3.38 (3H, s), 4.74-4.88 (1H, m) , 4.89-5.04 (1H, m), 6.18 (1H, d, J=3.40Hz), 7.27-7.48 (9H, m), 7.64-7.82 (3H, m) (-)ESI-MS (m/z): 549 (M-H)" 6) 3-Ethoxy-4'-[3-[[(2R)-2-hydroxy-2-phenylethyl]amino]- propyl]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-dg, 5): 1.54-1.87 (6H, m), 1.93-2.14 (4H, m) , 2.71 (2H, t, J=7.0Hz), 2.89-3.23 (4H, m), 3.38 (3H, s), 4.90-5.04 (1H, m), 6.18 (1H, d, J=3.60Hz), 7.25-7.71 (12H, m) (-)ESI-MS (m/z): 495 (M-H)" 7) 4'-[3-[[(2R)-2-Hydroxy-2-phenylethyl]amino]propyl]-3- isobutyl-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMS0-d6, 5): 0.87 (6H, d, J=6.53Hz), 1.71-2.18 (3H, m) , 2.63-2.80 (4H, m), 2.88-3.24 (4H, m), 3.38 (3H, s), 4.88-5.05 (1H, m), 6.18 (1H, d, J=4.0Hz), 7.26-7.44 (7H, m) , 7.49-7.73 (5H, m) , 12.19 (1H, s) (-)ESI-MS (m/z): 507 (M-H)~ (8) 3-Cyclopentyl-4'-[3-[[(2R)-2-hydroxy-2-phenylethyl]- amino]propyl]-N-(methylsulfonyl)-4-biphehylcarboxamide hydrochloride NMR (DMSO-d6, 5): 1.52-2.2 (10H, m), 2.71 (2H, t, J=7.3Hz), 2.87-3.23 (4H, m) , 3.39 (3H, s), 4.89-5.03 (1H, m), 6.18 (1H, d, J=3.5Hz), 7.28-7.44 (7H, m) , 7.44-7.59 (2H, m), 7.59-7.72 (3H, m), 12.21 (1H, s) (-)ESI-MS (m/z): 519 (M-H)" (9) 4'-[2-[ [(2R)-2-Hyxroxy-2-(3-pyridyl)ethyl]amino]ethyl]- 3-isobutoxy-N-(methylsulfonyl)-4-biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 6): 1.05 (6H, d, J=7Hz), 2.06-2.18 (1H, m) , 3.04-3.14 (2H, m), 3.17-3.3 (4H, m), 3.37 (3H, s), 4.04 (2H, d, J=6.2Hz), 5.2-5.27 (1H, m), 7.35-7.42 (4H, m), 7.71-7.79 (3H, m) , 7.84-7.9 (1H, m), 8.34 (1H7 d, J=7.7Hz), 8.76-8.87 (2H, m), 11.27 (1H, s) (-)ESI-MS (m/z): 510 (M-H)" (10) 4' ~[2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]- 3-isobutoxy-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-d6, 5): 1.02 (6H, d, J=3.29Hz), 1.99-2.12 (1H, m), 3.04-3.15 (2H, m), 3.18-3.31 (3H, m), 3.34-3.46 (1H, m), 3.93 (2Hr d, J=6.22Hz), 5.27-5.36 (1H, m), 7.24-7.31 (2H, m), 1.36-1.42 (2H, m) , 7.70-7.76 (3H, m), 7.96-8.04 (1H, m), 8.50 (1H, d, J=8.05Hz), 8.83-8.93 (2H, m) (-)ESI-MS (m/z): 433 (M-H)" (11) 4'-[2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]- 3-isobutyl-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-d6, 5): 0.88 (6H, d, J=6.53Hz), 1.73-1.97 (1H, m) , 2.99-3.52 (6H, m), 5.24-5.38 (1H, m), 7.39 (2H, d, J=8.03Hz), 7.49-7.62 (2H, m), 7.70 (2H, d, J=8.03Hz), 7.87 (1H, d, J=8.53Hz), 7.93-8.05 (1H, m), 8.50 (1H, d, J=8.53Hz), 8.79-8.96 (2H, m) (-)ESI-MS (m/z): 417 (M-H)~ (12) 4'-[3-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]- propyl]-3-isobutoxy-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-d6, 5): 1.02 (6H, d, J=6.59Hz), 1.98-2.11 (3H, m) , 2.49-2.52 (3H, m), 2.73 (2H, t, J=7.68Hz), 2.93-3.04 (2H, m), 3.11-3.23 (1H, m), 3.28-3.39 (1H, m), 3.93 (2H, d, J=6.59Hz), 5.24-5.31 (1H, m) , 7.23-7.38 (4H, m) , 7.66-7.75 (3H, m), 7.94-8.01 (1H, m), 8.48 (1H, d, J=8.05Hz), 8.81-8.91 (2H, m) (-)ESI-MS (m/z): 447 (M-H)~ (13) 4'-[3-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]- propyl]-3-isobutoxy-N-(methylsulfonyl)-4- biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 5): 1.05 (6H, d, J=6.59Hz), 1.93-2.19 (3H, m) , 2-.73 (2H, t, J=7.68Hz), 2.92-3.04 (2H, m) , 3.08-3.21 (1H, m), 3.24-3.35 (1H, m), 3.38 (1H, s), 4.04 (2H, d, J=6.22Hz), 5.12-5.24 (1H, m), 6.43-6.77 (1H, br), 7.33-7.41 (4H, m) , 7.69-7.84 (4H, m), 8.23-8.30 (1H, m) , 8.72-8.82 (2H, m), 11.3 (1H, s) (-)ESI-MS (m/z): 524 (M-H)~ Example 38 To a solution of tert-butyl [2-[4'-(aminosulfonyl)-3'-(cyclohexyloxy)-4-biphenylyl]ethyl][(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]carbamate (188 mg) in dichloromethane (2 ml) were added triethylamine (0.12 ml) and butanoyl chloride (0.087 ml) at approximately 0°C, and the mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate, washed with water, aqueous hydrochloric acid solution (0.5N) and brine, dried over sodium sulfate and evaporated under reduced pressure to give residue (230 mg). To a solution of the above residue in methanol (5 ml) was added 4-methylbenzenesulfonic acid (23 mg) at room temperature and the mixture was stirred overnight. The mixture was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 6/4) to give tert-butyl [2-[4'-[(butyrylamino)sulfonyl]-3'- (cyclohexyloxy)-4-biphenylyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]carbamate (145 mg). (-)ESI-MS (m/z): 663 (M-H)~ Example 39 To a solution of methyl 4'-[2-[(tert-butoxycarbonyl)- [(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(ethylthio)-4-biphenylcarboxylate (300 mg) in chloroform (6 ml) and N,N-dimethylformamide (3 ml) was added m-chloroperbenzoic acid (541 mg) and the mixture was stirred at room temperature for 1 hour. The mixture solution was poured into water and extracted with methylene chloride. The organic layer was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give a sulfone product. To a solution of the product in methanol (3 ml) was added aqueous solution of sodium hydroxide (IN, 867 \il) at room temperature and the mixture was stirred at 45°C for 3 hours. The mixture solution was acidified with hydrochloric acid aqueous solution, poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give a benzoic acid product. To a solution of the product in ethyl acetate (1.5 ml) was added hydrogen chloride ethyl acetate solution (4N, 1.5 ml) at 0°C and the mixture was stirred at room temperature overnight. The resultant solid was collected by filtration and dried to give 3-(ethylsulfonyl)-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]-ethyl]-4-biphenylcarboxylic acid hydrochloride (50 mg). NMR (DMSO-d6, 5): 1.21 (3H, t, J=3.7Hz), 3.03-3.27 (6H, m), 3.61 (2H, q, J=3.7Hz), 4.98 (1H, d, J=5Hz), 6.23 (1H, br s), 7.33-7.45 (7H, m), 7.76 (2H, d, J=4.1Hz), 7.84 (1H, d, J=4Hz), 8.09 (1H, dd, J-0.9, 4Hz), 8.13 (1H, d, J=0.9Hz), 8.87 (1H, br s), 9.15 (1H, br s) (-)ESI-MS (m/z): 452 (M-H)~ Example 4 0 The suspension of 4'- [2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylic acid hydrochloride in hydrogen chloride ethanol solution (5.5M, 1 ml) was stirred under reflux for 1.5 hours. The mixture solution was evaporated under reduced pressure and the resultant solid was washed with isopropyl ether to give ethyl 4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-3-(isopropylthio)-4-biphenylcarboxylate hydrochloride (37 mg). NMR (DMSO-d6, 5): 1.30 (6H, d, J=6.6Hz), 1.32 (3H, t, J=7.4Hz), 2.99-3.34 (6H, m), 3.71-3.84 (1H, m) , 4.3 (2H, q, J=7.1Hz), 4.97-5.02 (1H, m), 6.23 (1H, d, J=3.8Hz)/ 7.31-7.42 (7H, m) , 7.53 (1H, dd, J=1.4, 8.1Hz), 7.65 (1H, s), 7.72 (2H, d, J=8.2Hz), 7.88 (1H, d, J=8.1Hz) (+)ESI-MS (m/z): 464 (M+H)+ Example 41 To a solution of methyl 3-(acetylamino)-4'-[2-[benzyl[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-4-biphenylcarboxylate in ethyl acetate (6 ml) was added hydrogen chloride ethyl acetate solution (4N, 2 ml) and stirred for 30 minutes at room temperature. The mixture was poured into sodium hydroxide aqueous solution (IN) and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated to give methyl 3-(acetylamino)-4'-[2-[benzyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-4-biphenylcarboxylate (177 mg). (+)ESI-MS (m/z): 523 (M+H)+ Example 4 2 To a solution of benzyl [ (2R)-2- [4-(benzyloxy)-3- [(methylsulfonyl)amino]phenyl]-2-hydroxyethyl] [2- (4-bromophenyl)ethyl]carbamate (600 mg) and [3-isopropoxy-4- [(N-methanesulfonyl)carbamoyl]phenyl]boronic acid (365 mg) in 1,2-dimethoxyethane (9 ml) were added sodium carbonate aqueous solution (2M, 2.03 ml) and tetrakis- (triphenylphosphine)palladium (89.5 mg) at room temperature and stirred at 75°C for 10 hours under nitrogen. The mixture was poured into hydrochloric acid aqueous solution (1M) and ethyl acetate, added active carbon and stirred at room temperature for 2 hours. The mixture was filtrated and partitioned. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/3) to give a biphenyl product. To a solution of the biphenyl product (303 mg) in methanol (15 ml) was added palladium on carbon (150 mg), the atmosphere was replaced with hydrogen and stirred for 40 minutes at room temperature. The mixture was diluted with chloroform and filtrated. To the solution was added hydrogen chloride ethyl acetate solution (4N, 110 jil) and evaporated to give 4'-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)-amino]phenyl]ethyl]amino]ethyl]-3-isopropoxy-N-methylsulfonyl)-4-biphenylcarboxamide hydrochloride (188 mg). NMR (DMSO-d6, 5): 1.37 (6H, df J=6Hz), 2.9.5 (3H, s) , 3.38 (3H, s), 2.98-3.57 (6H, m) , 4.87 (1H, d, J=7.9Hz), 4.92-5.04 (1H, m) , 6.12 (1H, br s), 6.93 (1H, d, J=8.2Hz), 7.08 (1H, dd, J=1.9, 8.3Hz), 7.25 (1H, df J=1.8Hz), 7.36-7.41 (4H, m), 7.74 (2H, d, J=6.5Hz), 7.78 (1H, d, J=6.4Hz), 8.81 (1H, s), 8.85 (1H, br s), 9.11 (1H, br s), 10.03 (1H, s), 11.22 (1H, s) (-)ESI-MS (m/z): 604 (M-H)~ Example 4 3 To a solution of 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]ethyl]-3-isopropoxy-4-biphenylcarboxylic acid (224 mg) in N,N-dimethylformamide (2 ml) was added 1,1'-carbonyldiimidazole (72 mg) at room temperature and the mixture was stirred at the same temperature for 1 hour. 1-Pentanesulfonamide (67 mg) and 1,8-diazabicyclo[5.4.0]-7-undecene (0.067 ml) were added to the mixture at room temperature. The mixture was stirred at 70°C for 4 hours. After cooling down to room temperature, the mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid solution (0.5N) and brine, dried over sodium sulfate and evaporated under reduced pressure to give residue (403 mg). To a solution of the above residue in methanol (2 ml) was added 4-methylbenzenesulfonic acid at room temperature and the mixture was stirred at the same temperature for 2 days. The mixture was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 7/3) to give tert-butyl [(2R)-2-hydroxy-2-phenylethyl] [2-[3'-isopropoxy-4'-[[(pentylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl]carbamate (179 mg). (+)ESI-MS (m/z): 675 (M+Na)+ Example 4 4 A mixture of tert-butyl [ (2R)-2-hydroxy-2-phenylethyl] [2- (4-iodophenoxy)ethyl]carbamate (250 mg), [3-ethoxy-4-[[(methylsulfonyl)amino]carbonyl]phenyl]boronic acid (223 mg), [1,1'-bis(diphenylphosphino]ferrocene]-dichloropalladium(II), complex with dichloromethane (1:1, 114 mg), 1,1'-bis(diphenylphosphino)ferrocene (32 mg), N,N-dimethylformamide (5 ml), and 2N sodium carbonate solution (0.99 ml) was stirred at 80°C for 1 hour. After cooling to room temperature, the mixture was quenched by the addition of IN hydrochloric acid (1.99 ml) and partitioned between ethyl acetate (20 ml) and water (20 ml). The organic layer was separated, washed with water (20 ml x 2) and brine (20 ml), and dried over magnesium sulfate. Filtration followed by evaporation gave a brown foam which was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give tert-butyl [2-[[3'-ethoxy-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]oxy]ethyl][(2R)-2-hydroxy-2-phenylethyl]carbamate (84.5 mg) as a pale orange solid. (-)ESI-MS (m/z): 597 (M-H)~ Example 4 5 In a reaction vessel were added tert-butyl [(2R)-2-hydroxy-2-phenylethyl] [2- (4-iodophenoxy)ethyl]carbamate (200 mg) , [3-isopropoxy-4-[[(methylsulfonyl)amino]carbonyl]-phenyl]boronic acid (150 mg), [1,1'-bis(diphenylphosphino)-ferrocene]dichloropalladium(II), complex with dichloromethane (1:1, 33.8 mg), toluene (3.2 ml), ethanol (0.8 ml), and 2N sodium carbonate solution (0.66 ml). The vessel was placed in a microwave and irradiation was adjusted to keep the temperature 100°C and the reaction was performed for 2 hours. After cooling to room temperature, the mixture was quenched by the addition of IN hydrochloric acid (1.32 ml) and partitioned between ethyl acetate (20 ml) and water (20 ml). The organic layer was separated, washed with brine (20 ml), and dried over magnesium sulfate. Filtration followed by evaporation gave a brown foam which was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give tert-butyl [(2R)-2-hydroxy-2-phenylethyl]-[2- [ [3'-isopropoxy-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]oxy]ethyl]carbamate (20.4 mg) as a pale yellow solid. (-)ESI-MS (m/z): 611 (M-H)~ Example 4 6 A mixture of tert-butyl [2-[3'-(cyclohexyloxy)-4'- [[ (methylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl] [(2R)-2-hydroxy-2-(4-nitrophenyl)ethyl]carbamate (281 mg), iron powder (69.1 mg) , ammonium chloride (11 mg), ethanol (4.2 ml), and water (1.4 ml) was refluxed for 1 hour. After cooling to room temperature, the insoluble solid was filtered off through a Celite pad and washed with ethyl acetate (20 ml). The filtrate was washed with brine (20 ml) and dried over magnesium sulfate. Filtration followed by evaporation gave a yellow foam (271 mg) which was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give tert-butyl [(2R)-2-(4-aminophenyl)-2-hydroxyethyl]- [2- [3'-(cyclohexyloxy)-4'-[[(methylsulfonyl)amino]carbonyl]-4-biphenylyl]ethyl]carbamate (104 mg) as a pale yellow solid. (-)ESI-MS (m/z): 650 (M-H)~ Example 47 The following compounds were obtained according to a similar manner to that of Example 14. (1) 4'-[2-[[(2R)-2-(4-Aminophenyl)-2-hydroxyethyl]amino]- ethoxy]-3-isopropoxy-N-(methylsulfonyl)-4- biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 6): 1.38 (6H, d, J=6.2Hz), 3.05-3.29 (2H, m), 3.39 (3H, s), 3.42-3.49 (2H, m) , 4.34-4.43 (2H, m), 4.96-5.02 (2H, m), 6.23 (1H, br), 7.11 (2H, d, J=8.8Hz), 7.19 (2H, d, J=6.6Hz), 7.36 (1H, dd, J=1.5, 8.1Hz), 7.40-7.41 (3H, m), 7.77 (2H, d, J=8.8Hz), 7.78 (1H, d, J=8.1Hz), 8.97 (1H, br) , 9.19 (1H, br), 9.41 (2H, br), 11.2 (1H, br) (-)ESI-MS (m/z): 526 (M-H)~ (2) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-(2- methoxyethoxy)-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 3.0-3.5 (6H, m), 3.36 (3H, s), 3.39 (3H, s), 3.72-3.77 (2H, m), 4.41-4.45 (2H, m), 4.98-5.03 (1H, m), 6.23 (1H, d, J=6Hz), 7.31-7.85 (12H, m) , 8.6-9.6 (2-H, m) (3) 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-N- (methylsulfonyl)-3-(2,2,2-trifluoroethoxy)-4- biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 3.0-3.6 (6H, m), 3.32 (3H, s), 4.6- 5.1 (3H, m), 6.23 (1H, d, J=4Hz), 7.2-7.6 (9H, m) , 7.63 (1H, d, J=8Hz), 7.78 (2H, d, J=8.5Hz) (+)ESI-MS (m/z): 537 (M+H)+ (4) 3-(2-Fluoroethoxy)-4'-[2-[[(2R)-2-hydroxy-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4- biphenylcarboxamide hydrochloride (+JESI-MS (m/z): 501 (M+H)+ (5) 4'-[2-[[(lS,2R)-2-Hydroxy-l-methyl-2- phenylethyl]amino]ethyl]-N-(methylsulfonyl)-3-(2,2,2- trifluoroethoxy)-4-biphenylcarboxamide hydrochloride (-)ESI-MS (m/z): 549 (M-H)" (6) 3-(3-Fluoropropoxy)-4'-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 6): 2.13-2.23 (2H, m) , 3.02-3.35 (6H, m) , 3.34 (3H, s), 4.32 (2H, t, J=6.1Hz), 4.6-4.75 (2H, m) , 4.95-4.99 (1H, m), 6.23 (1H, d, J=4Hz), 7.31-7.41 (9H, m) , 7.67 ,(1H, d, J=8Hz) , 7.76 (2H, d, J=8.2Hz) ( + )ESI-MS (m/z).: 515 (M+H)+ (free) 7) 3-(3-Fluoropropoxy)-4'-[2-[[(IS,2R)-2-hydroxy-l-methyl-2-phenylethyl]amino]ethyl]-N-(methylsulfonyl)-4-biphenylcarboxamide hydrochloride NMR (DMSO-d6, 5): 0.97 (3H, d, J=6.7Hz), 2.14-2.23 (2H, m) , 3.08-3.48 (5H, m), 3.35 (3H, s), 4.31-4.34 (2H, m) , 4.61-4.76 (2H, m) , 5 .18-5.21 '(1H, m) , 6.16 (1H, d, J=4.3Hz), 7.27-7.77 (9H, m), 7.67 (1H, d, J=8Hz), 7.77 (2H, d, J=8.3Hz) (+)ESI-MS (m/z): 529 (M+H)+ (8) 4'-[2-[ [ (2R)-2-(4-Aminophenyl)-2-hydroxyethyl]amino]-ethoxy]-3-(cyclohexyloxy)-N-(methylsulfonyl)-4-biphenylcarboxamide dihydrochloride NMR (DMSO-d6, 5): 1.34-1.64 (6H, m) , 1.69-1.78 (2H, m), 1.93-2.01 (2H, m) , 3.04-3.15 (1H, m) , 3.21-3.30 (1H, m), 3.39 (3H, s), 3.42-3.48 (2H, m), 4.34-4.43 (2H, m), 4.83 (1H, heptuplet, J=3.7Hz), 5.02 (1H, dd, J=1.8, 10.3Hz), 6.25 (1H, br), 7.12 (2H, d, J=8.8Hz), 7.24 (2H, d, J=7.7Hz), 7.35 (1H, dd, J=1.5, 8.1Hz), 7.42-7.44 (3H, m), 7.76 (2H, d, J=8.8Hz), 7.78 (1H, d, J=8.1Hz), 9.00 (1H, br), 9.26 (1H, br), 9.60 (2H, br), 11.1 (1H, br) (-)ESI-MS (m/z): 566 (M-H)~ (9) 4'-[2-[[(2R)-2-(3-Aminophenyl)-2-hydroxyethyl]amino]-ethyl]-3-(cyclohexyloxy)-N-(methylsulfonyl)-4-biphenylcarboxamide dihydrochloride NMR , 7.1-7.8 (12H, m) MS (m/z): 448 (M+H) (26) 4'-[3-[[(2R)-2-Hydroxy-2-phenylethyl]amino]propyl]-3- isopropoxy-4-biphenylcarboxylic acid hydrochloride NMR (DMS0-d6, 5): 1.29 (6H, d, J=6.0Hz), 1.7-2.2 (2H, m) , 2.7-3.4 (6H, m), 4.78 (1H, m), 4.93 (1H, m), 6.17 (1H, m), 7.1-7.8 (12H, m) MS (m/z): 434 (M+H) (27) 4' [2-[[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1- methylethyl]amino]ethoxy]-3-isopropoxy-4- biphenylcarboxylic acid hydrochloride NMR (DMSO-dg, 5): 1.09 (3H, d, J=6.2Hz), 1.33 (3H, d, J=6.0Hz), 3.0-3.4 (2H, m) , 4.2-4.4 (2H, m), 4.81 (1H, m), 5.06 (1H, m) , 5.98 (1H, m) , 6.35 (2H, m, J=8.4Hz), 7.0-7.5 (6H, m), 7.6-7.8 (3H, m) MS (m/z): 466 (M+H) (28) 3-Ethoxy-4'-[2-[[(IS,2R)-2-hydroxy-2-(4-hydroxyphenyl)- 1-methylethyl]amino]ethyl]-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-dg, 5): 1.00 (3H, d, J=6.6Hz), 1.33 (3H, t, J=6.8Hz), 3.0-3.7 (5H, m), 4.20 (2H, q, J=6.8Hz), 5.12 (1H, m), 5.98 (1H, m) , 6.79 (2H,d, J=8.4Hz), 7.1-7.6 (6H, m) , 7.7-7.9 (3H, m) MS (m/z): 436 (M+H) (29) 4'-[2-[[(IS,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1- methylethyl]amino]ethyl]-3-propoxy-4-biphenylcarboxylic acid hydrochloride NMR (DMSO-dg, 5): 0.8-1.1 (6H, m), 1.6-1.9 (2H, m), 3.0-3.7 (5H, m), 4.11 (2H, q, J=6.8Hz), 5.10 (1H, m), 5.99 (1H, m), 6.72 (2H, d, J=8.4Hz), 7.1-7.4 (6H, m), 7.5-7.8 (3H, m) MS (m/z): 449 (M+H) (30) 4'-[2-[[(lS,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-l- methylethyl]amino]ethyl]-3-isopropoxy-4- biphenylcarboxylic acid hydrochloride NMR (DMSO-dg, 5): 0.96 (3H, d, J=6.6Hz), 1.30 (6H, d, J=5.9Hz), 3.0-3.7 (5H, m) , 4.76 (1H, m), 5.08 (1H, m), 5.99 (1H, m), 6.72 (2H, d, J=8.4Hz), 7.1-7.4 (6H, m), 7.6-7.8 (3H, m) MS (m/z): 450 (M+H) (31) 4'-[2-[[(IS,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1- methylethyl]amino]ethyl]-3-isobutoxy-4- biphenylcarboxylic acid hydrochloride NMR (DMSO-dg, 5): 0.96 (3H, d, J=6.6Hz), 1.10 (6H, d, • J=5..9Hz), 2.0 (1H, m) , 3.0-3.7 (5H, m) , 3.99 (2H, m), 5.05 (1H, m), 5.99 (1H, m) , 6.72 (2H, d, J=8.4Hz), 7.1-7.4 (6H, m), 7.6-7.8 (3H, m) MS (m/z): 464 (M+H) (32) 3-(Cyclohexyloxy)-4'-[2-[[(IS,2R)-2-hydroxy-2-(4- hydroxyphenyl)-1-methylethyl]amino]ethyl]-4- biphenylcarboxylic acid hydrochloride NMR (DMSO-d6, 5): 1.2-2.0 (10H, m), 3.0-3.7 (5H, m), 4.64 (1H, m), 5.09 (1H, m), 5.99 (1H, m), 6.72 (2H, d, J=8.4Hz), 7.1-7.4 (6H, m), 7.6-7.8 (3H, m) MS (m/z): 490 (M+H) (33) 4'-[3-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]- propyl]-3-propoxy-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-dg, 5): 1.22 (3H, d, J=5.9Hz), 1.8-2.1 (4H, m), 2.5-3.3 (6H, m) , 4.08 (2H, t, J=7Hz), 5.29 (1H, m) , 6.9 (1H, m)> 7.1-7.3 (4H, m) , 7.6-7.8 (2H, m), 7.99 (1H, m), 8.5 (1H, m) , 8.86 (1H, m), 9.2 (2H, m) MS (m/z): 435 (M+H) (34) 3-(Cyclohexyloxy)-4'-[(2S)-3-hydroxy-2-[[(2R)-2- hydroxy-2-phenylethyl]amino]propyl]-N-(methylsulfonyl)- 4-biphenylcarboxamide hydrochloride NMR (DMSO-dg, 5): 1.1-2.1 (10H, m), 3.23 (3H, s), 2.8-3.7 (7H, m), 4.80 (1H, m), 5.09 (1H, m), 5.44 (1H, m), 6.20 (1H, m), 7.1-7.8 (12H, m) MS (m/z): 567 (M+H) (35) 4'-[2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]- N-(methylsulfonyl)-3-phenoxy-4-biphenylcarboxamide dihydrochloride NMR (DMSO-dg, 5): 3.0-3.3 (6H, m), 3.33 (3H, s), 4.82 (1H, m), 5.10 (1H, m), 7.0-7.8 (13H, m), 8.0-8.2 (1H, m), 8.6-8.8 (2H, m) MS (m/z): 532 (M+H) (36) 4'-{2-[ [(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-N- (methylsulfonyl)-3-phenoxy-4-biphenylcarboxamide hydrochloride NMR (DMSO-dg, 5): 3.0-3.3 (6H, m) , 3.33 (3H, s), 4.82 (1H, m), 5.02 (1H, m), 6.20 (1H, m), 7.1-7.5 (12H, m), 7.5-7.9 (5H, m) MS (m/z): 531 (M+H) (37) 4'-[2-[ [ (2R)-2-[3-(Benzyloxy)phenyl]-2-hydroxyethyl]- (tert-butoxycarbonyl)amino]ethyl]-3-isopropoxy-4- biphenylcarboxylic acid methyl ester MS (m/z): 640 (M+H) Example 67 The following compound was obtained according to a similar manner to that of Example 1 followed by a similar manner to that of Example 54. 4'-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-(3-pyridyloxy)-4-biphenylcarboxylic acid dihydrochloride NMR (DMSO-dg, 5): 3.0-3.2 (6H, m), 4.95-5.2 (1H, m) , 7.3-7.4 (7H, m), 7.6-7.8 (6H, m) , 7.7-8.0 (5H, m) , 8.03 (1H, d, J=8.2Hz), 8.42-8.51 (2H, m), 8.89 (1H, br), 9.22 (1H, br) MS (m/z): 453 (M-2HC1-H)" Example 68 To a mixture of tert-butyl [3-(4-bromophenyl)propyl]- [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]carbamate (312 mg), [3-isobutoxy-4-(methoxycarbonyl)phenyl]boronic acid (207 mg)f [1,1' -bis(diphenylphosphino)ferrocene]palladium(II) dichloride (58.4 mg) and 1,1'-bis(diphenylphosphino)-ferrocene (7.93 mg) in N,N-dimethylformamide (3.12 ml) was added 2.0M aqueous sodium carbonate solution (1.25 ml) and the mixture was stirred at 90°C for 2.5 hours. After cooling to room temperature, palladium was removed by filtration through a Celite cake. The mixture was extracted with ethyl acetate and the extract was washed with water and brine and dried over magnesium sulfate. Filtration followed by evaporation under reduced pressure gave a crude product which was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give methyl 4'- [3-[ (tert-butoxycarbonyl)[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]-propyl]-3-isobutoxy-4-biphenylcarboxylate (374 mg) as a yellow solid (foam). (+)ESI-MS (m/z): 563